Sanofi, the French pharmaceutical company, announced on Thursday a significant investment of €1.3 billion in the construction of a new insulin production facility in Germany. Located at its site near Frankfurt, the state-of-the-art facility, with an area of 36,000 square meters, will replace existing production plants by 2029.
This investment underscores Sanofi's commitment to ensuring a stable and long-term supply of essential insulin for people living with diabetes across Europe. The company aims to strengthen the resilience of the European supply chain through this new facility.
The project has garnered support from the German federal government, the state government of Hesse, and the city of Frankfurt, signalling the importance of the biopharmaceutical industry in the region.
Sanofi's Hoechst site plays a crucial role in the company's insulin production, encompassing the entire production chain, from the manufacture of active ingredients to the assembly of delivery devices.
This investment follows a trend of major pharmaceutical companies expanding their production capacity in Europe. In recent months, companies like Eli Lilly and Novo Nordisk have also announced significant investments in Germany and France.
While expanding its presence in Germany, Sanofi is not neglecting its home country. The company recently announced a historic investment of nearly €1.1 billion in France, including the construction of a new factory for monoclonal antibodies.
